INTRODUCTION AND AIMS:
This year marks the 90th anniversary of the first use of heparin in hemodialysis and 50 years since heparin was switched on in a combined treatment regimen for some active forms of glomerulonephritis. METHODS: In 1916, J. McLean was a second-year student at the Johns Hopkins University School of Medicine and a pupil of W.H. Howell isolated from dog liver cells a phosphatide that had anticoagulant properties and described its observations in the American Journal of Physiology. The following year, he made up of practicing medicine. In 1918 W.H. Howell together with his other student L.E. Holt singled out another anticoagulant and called it heparin. The dispute about the authorship of the discovery of heparin continues to the present day. Some point to J. McLean, others call W. H. Howell. The attempt to nominate J. McLean for the Nobel Prize (posthumously) was rejected, but evidently his discovery changed the vector of research W.H. Howell. In 1933 -1937 , the Canadian physiologist C. Best and his colleagues continued their research to obtain a low-toxicity heparin. The end of the 40's with the production of purified drug began the era of heparin therapy. In the second half of 80's were created a variety of drugs of low molecular weight heparins. RESULTS: Heparin belongs to a class of antithrombotic drugs. Blocking of the process of intravascular (intraglomerular) coagulation heparin reduces of the kidney immune inflammation. Heparin is not only an anticoagulant; it has diuretic, natriuretic, antihypertensive, antiproteinuric, anticomplementary, anti-inflammatory and lipolytic effects that is affects many manifestations of chronic kidney disease (CKD). On January 13, 1928, G. Haas first used heparin in hemodialysis for a man with end stage renal disease. In 1968, P. Kincaid-Smith published the results of heparin treatment of the first group of patients with oliguric acute renal failure due to diffuse proliferative glomerulonephritis (3 patients), polyarteritis nodosa (2 patients), and thrombotic thrombocytopenic purpura (1 patient). Today heparin is the main drug for the treatment and prevention of acute venous thrombosis complicating the nephrotic syndrome. It is prescribed in some forms of active glomerulonephritis in combination with steroids and immunosuppressive drugs. It is used to treat thrombotic microangiopathy with renal disorder due to typical and atypical hemolytic uremic syndrome and after kidney transplantation. Its purpose is indicated in patients with acute nephropathy and lupus nephritis associated with antiphospholipid syndrome. He is prescribed for the prophylaxis of deep vein thrombosis and other trombotic complications in patients with acute and chronic renal insufficiency. Heparin is a standard anticoagulant therapy in patients on hemodialysis. The use of heparin in pregnant women with CKD increases the frequency of a favorable neonatal outcome. CONCLUSIONS: Heparin is an important component of drug therapy in nephrologic patients. Clinic of nephrology, University of Nis, Nis INTRODUCTION AND AIMS: Hypertension is now recognized as an independent risk factor for the development of cardiovascular diseases. The main goal of arterial hypertension is a long term reduction in overall cardiovascular risk. A key success factor in the treatment of arterial hypertension is its recognition and proper therapeutic approach. METHODS: Historical data was connected for litearture, scientific periodicals, encyclopedias and laboratory data.
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RESULTS:
For elevated blood pressure, more than 2600 years have been known during which the number of knowledge and wounded research has been reached with the aim of treating it not only as symptomatic. The first research on hypertension was done by an English physiologist who lived in the eleventh century Stephen Hales, whle Laennec describing year 1819 the signs of left ventricular hypertrophy. Janeway introduced year 1913 the initial title , hypertensive vascular disease". Frank later year 1925 replaced that name the new ones , hypertonie essential". Richard Bright studied the relationship between the thickness of the renal artery an kidney disease in 1936 year. Tgraube in year 1856 showed that there was a relationship between hypertension, kidney disease, and hypertrophy of the heart. Many clinicians have linked hypertension to chronic Bright s disease as long as Mahomed did not first recognize the condition that Janeway later called in year 1913 ,essential hypertension". Whatever, Mahomed among the first to point out that healthy people cab have high blood pressure,this finding is also with aging, high blood pressure leads to heartburn , brain and kidney, and triggers the circulatory system for kidney damage by hypertension, he introduced epidemiological studies of hypertension. Only fifty years ago, thiazide diuretics were detected and their introduction into the treatment of hypertension was discovered and since then they have dated the number of studies in relation to therapeutic protocols and the outcome of treatment. CONCLUSIONS: Understanding pathophysiology of high blood pressure , wich is the most common disease, is still incomplete, and the success in treating hypertension is still uncertain. c) described anathomical location of the kidneys,the ureters,and the urethra, He also described a disease with renal sclerosis and suggested that haematuria is due to a widening of the renal tissue.The origin of the dia- 
